In June 2023 we published two important updated reviews on the Cochrane Library.
Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis - authors included four new studies which led to a change in the review's conclusions that nebulised antibiotics, alone or in combination with oral antibiotics, were better than no treatment for early infection with Pseudomonas aeruginosa and eradication may be sustained for up to two years. However, there is still insufficient evidence as to whether any antibiotic strategies decrease mortality or morbidity, improve quality of life, or are linked to adverse effects compared to placebo or standard treatment. The review found no differences in rates of eradication of P aeruginosa between active treatments, but did find evidence that intravenous antibiotic treatment is not superior to oral antibiotics. Read more details here.
Our review of gastro-intestinal issues 'Thinking outside the box: a review of gastrointestinal symptoms and complications in cystic fibrosis' was also published in June 2023, read it here.
CF Australia have published the first four chapters of their updated 'Standards of Care for Cystic Fibrosis' document which cites two of our reviews. Click here to access the current version and stay updated with upcoming chapters.
We have been successful in obtaining funding to the end of March 2025 to be able to continue with a programme of CF reviews and evidence syntheses to support guidelines. We would like to document our gratitude to the CF Foundation and the UK CF Trust for awarding us this grant. More details here.
Learn about our contributions to the "Standards of care for CFTR variant-specific therapy for people with CF" here.
Learn about our collaboration with the JLA here.
|We would like to thank our funders the CF Foundation and the UK CF Trust.